You are here

A Quality Ensuring Project With Focus On Patients With Cardiovascular Diseases As Well As Type 2 Diabetes.

Last updated on April 10, 2018

FOR MORE INFORMATION
Study Location
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Heart Diseases, Type 2 Diabetes Mellitus
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18+ years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Subjects had to meet all of the inclusion criteria to be eligible for enrollment into
the study. The following subjects qualify for inclusion in the study:

- Subjects for whom measurement of total cholesterol, low density lipoprotein (LDL)
cholesterol, blood pressure (BP) and glycosylated hemoglobin (HbA1c) was planned
independently of this observational study and for whom baseline values were or became
available.

- Subjects with known CVD diagnosed > or = 6 months before inclusion

- Previous myocardial infarction

- Ischemic heart disease (stable and unstable angina pectoris)

- Ischemic apoplexy

- Peripheral arterial disease

- And/Or

- Subjects with T2D diagnosed > or = 6 months before inclusion

- At least 50% of the subjects had to have CVD as the primary diagnosis. It was allowed
for a secondary diagnosis to be

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Subjects presenting with any of the following were not to be included in the study:

- Life expectancy of

- Unable/unwilling to understand/follow instructions

- Taking part in a clinical study involving an investigational drug

- Followed by a specialist for their CVD and/or T2D at the time of inclusion in the
study

NCT00415428
Pfizer
Completed
A Quality Ensuring Project With Focus On Patients With Cardiovascular Diseases As Well As Type 2 Diabetes.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.

Similar Trials

Part 1, MELANOMA, SCCHN, OVCA, SARCOMA, OTHER SOLID TUMORS, Part 1 and 2, NSCLC, UROTHELIAL CARCINOMA
NCT02573259
All Genders
18+
Years
Multiple Sites
Breast Neoplasms, BRCA 1 Gene Mutation, BRCA 2 Gene Mutation
NCT01945775
All Genders
18+
Years
Multiple Sites
A Quality Ensuring Project With Focus On Patients With Cardiovascular Diseases As Well As Type 2 Diabetes.
Patient And Physician Alliance -Guideline Education Treatment Optimization
The overall objective is to increase the adherence to national guidelines for patients with established CVD and/or Type 2 diabetes by means of repeated post-graduate educational meetings and regular evaluation of the optimisation initiatives, demonstrated by improvement of goal attainment in general practice.
Not Provided
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Probability Sample
Primary care clinic patients
  • Heart Diseases
  • Diabetes Mellitus, Type 2
Behavioral: Patient adherence to national educational guidelines.
1.
Not Specified
Intervention: Behavioral: Patient adherence to national educational guidelines.
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
2776
September 2008
September 2008   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Subjects had to meet all of the inclusion criteria to be eligible for enrollment into the study. The following subjects qualify for inclusion in the study:
  • Subjects for whom measurement of total cholesterol, low density lipoprotein (LDL) cholesterol, blood pressure (BP) and glycosylated hemoglobin (HbA1c) was planned independently of this observational study and for whom baseline values were or became available.
  • Subjects with known CVD diagnosed > or = 6 months before inclusion
  • Previous myocardial infarction
  • Ischemic heart disease (stable and unstable angina pectoris)
  • Ischemic apoplexy
  • Peripheral arterial disease
  • And/Or
  • Subjects with T2D diagnosed > or = 6 months before inclusion
  • At least 50% of the subjects had to have CVD as the primary diagnosis. It was allowed for a secondary diagnosis to be <6 months before inclusion.

Exclusion Criteria:

  • Subjects presenting with any of the following were not to be included in the study:
  • Life expectancy of < or = 2 years
  • Unable/unwilling to understand/follow instructions
  • Taking part in a clinical study involving an investigational drug
  • Followed by a specialist for their CVD and/or T2D at the time of inclusion in the study
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
Denmark
 
NCT00415428
A2581154
Not Provided
Not Provided
Not Provided
Pfizer
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
April 2015

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now